Human immunodeficiency virus type 1 antigens (HIV-1 antigens) (HIV-1 antigens)

Human immunodeficiency virus type 1 (HIV-1) antigens encompass a variety of viral proteins, including structural (Gag), enzymatic (Pol), and envelope (Env) components such as gp120 and gp41 (UniProt, 2023). These antigens serve as the primary targets for the host immune system during natural infection and are the fundamental components of experimental HIV vaccines and immunotherapies (NIAID, 2023). Unlike traditional pharmacological targets where a drug binds to inhibit a specific enzymatic or signaling function, these antigens are utilized to elicit or be recognized by immune effectors like antibodies and T-cells. Their biological role involves mediating viral entry into host CD4+ cells, processing viral polyproteins, and facilitating the assembly of new virions (PubMed, 2022). In the context of disease, they are central to the pathogenesis of HIV/AIDS by driving viral replication and contributing to immune system depletion. Therapeutic strategies focusing on these antigens include the development of broadly neutralizing antibodies (bNAbs) and various vaccine platforms designed to induce long-lasting protective immunity (Nature Reviews Drug Discovery, 2021).

Other names

HIV-1 proteinsHIV-1 viral proteinsHIV-1 structural proteinsHIV-1 envelope proteinsgp120gp41p24Gag-Pol-Env

Induction of humoral and cellular immune responses, including the production of neutralizing antibodies and activation of cytotoxic T lymphocytes, to prevent or control viral infection (NIH, 2023; PubMed, 2022).